MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Lack of immunogenicity of incobotulinumtoxinA in pediatrics: A pooled analysis

F. Heinen, M. Banach, E. Dabrowski, D. Gaebler-Spira, H. Chambers, S. Schroeder, T. Geister, M. Althaus, A. Hanschmann, S. Berweck (Munich, Germany)

Meeting: 2022 International Congress

Abstract Number: 222

Keywords: Botulinum toxin: Clinical applications: other, Botulinum toxin: Clinical applications: spasticity, Cerebral palsy

Category: Pediatric Movement Disorders

Objective: To present pooled data analyses of the immunogenicity of incobotulinumtoxinA (INCO) in pediatrics.

Background: BotulinumtoxinA (BoNT-A) is used to treat several chronic pediatric conditions, including spasticity and sialorrhea (excessive drooling). As with other biologic drugs, repeated use of BoNT-A can cause antibody (AB) formation leading to clinical non-responsiveness, a clinically challenging problem [1]. Because INCO, the most purified BoNT-A, is free from complexing proteins, it is thought to carry a low risk of inducing an immunogenic response [2].

Method: This was a pooled analysis of available AB data from four phase 3 studies of children/adolescents (2–17 years) investigating INCO for the treatment of limb spasticity associated with cerebral palsy [Treatment with IncobotulinumtoxinA in Movement (TIM), Treatment with IncobotulinumtoxinA in Movement Open-label (TIMO), incobotulinumtoXinA in aRm treatment in cerebral pAlsy (XARA)] or sialorrhea [Sialorrhea Pediatric Xeomin Investigation (SIPEXI)] associated with neurological disorders in children/adolescents. Full methodological details can be found in [3–6]. Figure 1 [figure1] shows INCO doses, number/frequency of injection cycles (ICs), and timing of AB testing. Patient samples were first screened using fluorescence immunoassay (FIA) to detect antibodies against BoNT and, if positive, further testing for neutralizing (NAB) titers was performed using the mouse ex vivo hemidiaphragm assay (HDA). Data were pooled across INCO doses. AB testing was limited to patients ≥21 kg/≥30 kg body weight for the spasticity/sialorrhea studies, respectively.

Results: Of 1159 patients treated with INCO [Table 1], 520 were eligible for AB testing at screening and 422 (81.2%) test results were available; 60 (11.5%) had a positive FIA test at screening and 54 (8.8%) were positive at the last visit. Using the HDA, 10 (1.9%) tested positive for NABs at screening and 10 (1.6%) were NAB positive at the last visit [Table 2]. Analysis of the subpopulation with known pre-treatment status showed that no BoNT-naïve patients developed NABs after INCO; all children with positive NAB tests had previously been treated with a BoNT other than INCO [Table 3].

Conclusion: INCO carries a very low risk of inducing an immunogenic response with long-term use, and this can be an important determinant when selecting treatment for children/adolescents with chronic conditions.

Heinen neutralizing antibodies Table 1

Heinen neutralizing antibodies Table 2

Heinen neutralizing antibodies table 3

Heinen figure 1

References: 1. Carr WW, Jain N, Sublett JW. Immunogenicity of Botulinum Toxin Formulations: Potential Therapeutic Implications. Adv Ther. 2021;38(10):5046-64. doi: 10.1007/s12325-021-01882-9.
2. Kerscher M, Wanitphakdeedecha R, Trindade de Almeida A, Maas C, Frevert J. IncobotulinumtoxinA: A Highly Purified and Precisely Manufactured Botulinum Neurotoxin Type A. J Drugs Dermatol. 2019;18(1):52-7.
3. Heinen F, Kaňovský P, Schroeder AS, Chambers HG, Dabrowski E, Geister TL, et al. IncobotulinumtoxinA for the treatment of lower-limb spasticity in children and adolescents with cerebral palsy: A Phase 3 study. J Pediatr Rehabil Med, 2021; 14(2): 183-97. doi: 10.3233/PRM-210040.
4. Kaňovský P, Heinen F, Schroeder AS, Chambers HG, Dabrowski E, Geister TL, et al. Safety and efficacy of repeat long-term incobotulinumtoxinA treatment for lower limb or combined upper/lower limb spasticity in children with cerebral palsy. J Pediatr Rehabil Med (in press), 2021. doi: 10.3233/PRM-210041.

5. Dabrowski E, Chambers HG, Gaebler-Spira D, Banach M, Kaňovský P, Dersch H, et al. IncobotulinumtoxinA efficacy/safety in upper-limb spasticity in pediatric cerebral palsy: Randomized controlled trial. Pediatric Neurology 2021; 123: 10-20. doi: 10.1016/j.pediatrneurol.2021.05.014.

6. Berweck S, Bonikowski M, Kim H, Althaus M, Flatau-Baqué B, Mueller D, Banach MD. Placebo-Controlled Clinical Trial of IncobotulinumtoxinA for Sialorrhea in Children: SIPEXI. Neurology. 2021;97(14):e1425–36. doi: 10.1212/WNL.0000000000012573.

To cite this abstract in AMA style:

F. Heinen, M. Banach, E. Dabrowski, D. Gaebler-Spira, H. Chambers, S. Schroeder, T. Geister, M. Althaus, A. Hanschmann, S. Berweck. Lack of immunogenicity of incobotulinumtoxinA in pediatrics: A pooled analysis [abstract]. Mov Disord. 2022; 37 (suppl 2). https://www.mdsabstracts.org/abstract/lack-of-immunogenicity-of-incobotulinumtoxina-in-pediatrics-a-pooled-analysis/. Accessed May 14, 2025.
  • Tweet
  • Email
  • Print

« Back to 2022 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/lack-of-immunogenicity-of-incobotulinumtoxina-in-pediatrics-a-pooled-analysis/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley